Vivatides Therapeutics
PrivateLast Round
Series A
Apr 10, 2026
Total Funding Raised
$64M
Company Overview
Vivatides Therapeutics is a biotechnology company developing extrahepatic RNA-targeting therapeutics, including small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), to treat chronic conditions.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivatides Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Vivatides Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 10, 2026 | ||||
| Seed | Aug 22, 2025 |
Vivatides Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Highlight Capital | Series A |
| TF Capital | Series A |
| Qiming Venture Partners | Seed, Series A |
| Apricot Capital | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
Raised $54M in Series A funding.
- Aug 22, 2025
$10M raised in Seed round.
Vivatides Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vivatides Therapeutics's valuation, stock price, and market status.
